Holmium for Use in Cancer Therapy

Yi Shi, Amanda Melia Johnsen, Anthony J. Di Pasqua

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Over the last few decades, holmium (Ho) has been investigated for its application in laser surgery, magnetic resonance imaging, and internal and topical radionuclide therapy. Ho has a 100% natural abundance of holmium-165, which is a stable nuclide that can undergo a process called neutron-activation to generate radioactive holmium-166 (166Ho). 166Ho emits βparticles and γ photons, with a half-life of 26.8 h; βparticles can damage a cancer cell’s DNA, while γ photons allow for 166Ho to be imaged in vivo and easily quantitated prior to, or during, dosing. This article gives a thorough account of the work being done around the world on 166Ho for use as an internal or topical radionuclide therapy against cancer. Our research group and others have generated compelling data that support the use of 166Ho as a radiotherapeutic in the clinic, especially since pharmaceutical formulations can be made while non-radioactive (Ho) and then made radioactive (166Ho) just prior to use.

Original languageEnglish (US)
Pages (from-to)281-300
Number of pages20
JournalComments on Inorganic Chemistry
Volume37
Issue number6
DOIs
StatePublished - Nov 2 2017

Fingerprint

Holmium
Radioisotopes
Photons
Laser surgery
Magnetic resonance
Isotopes
Neutrons
Chemical activation
Cells
Imaging techniques
DNA
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Inorganic Chemistry

Cite this

Shi, Yi ; Johnsen, Amanda Melia ; Di Pasqua, Anthony J. / Holmium for Use in Cancer Therapy. In: Comments on Inorganic Chemistry. 2017 ; Vol. 37, No. 6. pp. 281-300.
@article{e6fa51c064b14b83a2aa2563ec9c249b,
title = "Holmium for Use in Cancer Therapy",
abstract = "Over the last few decades, holmium (Ho) has been investigated for its application in laser surgery, magnetic resonance imaging, and internal and topical radionuclide therapy. Ho has a 100{\%} natural abundance of holmium-165, which is a stable nuclide that can undergo a process called neutron-activation to generate radioactive holmium-166 (166Ho). 166Ho emits β–particles and γ photons, with a half-life of 26.8 h; β–particles can damage a cancer cell’s DNA, while γ photons allow for 166Ho to be imaged in vivo and easily quantitated prior to, or during, dosing. This article gives a thorough account of the work being done around the world on 166Ho for use as an internal or topical radionuclide therapy against cancer. Our research group and others have generated compelling data that support the use of 166Ho as a radiotherapeutic in the clinic, especially since pharmaceutical formulations can be made while non-radioactive (Ho) and then made radioactive (166Ho) just prior to use.",
author = "Yi Shi and Johnsen, {Amanda Melia} and {Di Pasqua}, {Anthony J.}",
year = "2017",
month = "11",
day = "2",
doi = "10.1080/02603594.2017.1333498",
language = "English (US)",
volume = "37",
pages = "281--300",
journal = "Comments on Inorganic Chemistry",
issn = "0260-3594",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

Holmium for Use in Cancer Therapy. / Shi, Yi; Johnsen, Amanda Melia; Di Pasqua, Anthony J.

In: Comments on Inorganic Chemistry, Vol. 37, No. 6, 02.11.2017, p. 281-300.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Holmium for Use in Cancer Therapy

AU - Shi, Yi

AU - Johnsen, Amanda Melia

AU - Di Pasqua, Anthony J.

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Over the last few decades, holmium (Ho) has been investigated for its application in laser surgery, magnetic resonance imaging, and internal and topical radionuclide therapy. Ho has a 100% natural abundance of holmium-165, which is a stable nuclide that can undergo a process called neutron-activation to generate radioactive holmium-166 (166Ho). 166Ho emits β–particles and γ photons, with a half-life of 26.8 h; β–particles can damage a cancer cell’s DNA, while γ photons allow for 166Ho to be imaged in vivo and easily quantitated prior to, or during, dosing. This article gives a thorough account of the work being done around the world on 166Ho for use as an internal or topical radionuclide therapy against cancer. Our research group and others have generated compelling data that support the use of 166Ho as a radiotherapeutic in the clinic, especially since pharmaceutical formulations can be made while non-radioactive (Ho) and then made radioactive (166Ho) just prior to use.

AB - Over the last few decades, holmium (Ho) has been investigated for its application in laser surgery, magnetic resonance imaging, and internal and topical radionuclide therapy. Ho has a 100% natural abundance of holmium-165, which is a stable nuclide that can undergo a process called neutron-activation to generate radioactive holmium-166 (166Ho). 166Ho emits β–particles and γ photons, with a half-life of 26.8 h; β–particles can damage a cancer cell’s DNA, while γ photons allow for 166Ho to be imaged in vivo and easily quantitated prior to, or during, dosing. This article gives a thorough account of the work being done around the world on 166Ho for use as an internal or topical radionuclide therapy against cancer. Our research group and others have generated compelling data that support the use of 166Ho as a radiotherapeutic in the clinic, especially since pharmaceutical formulations can be made while non-radioactive (Ho) and then made radioactive (166Ho) just prior to use.

UR - http://www.scopus.com/inward/record.url?scp=85020752632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020752632&partnerID=8YFLogxK

U2 - 10.1080/02603594.2017.1333498

DO - 10.1080/02603594.2017.1333498

M3 - Review article

AN - SCOPUS:85020752632

VL - 37

SP - 281

EP - 300

JO - Comments on Inorganic Chemistry

JF - Comments on Inorganic Chemistry

SN - 0260-3594

IS - 6

ER -